Inhibikase Therapeutics Inc Stock Price, News & Analysis

Inhibikase Therapeutics (NASDAQ: IKT) on Nov 20, 2025 announced a proposed underwritten public offering of common stock and, for some investors, pre-funded warrants exercisable for common stock. The company also intends to grant underwriters a 30‑day option to purchase up to an additional 15% of the shares at the public offering price, less underwriting discounts and commissions.

The offering is being made from a shelf registration on Form S-3 (No. 333-288213) declared effective June 27, 2025, is subject to market and other conditions, and may not be completed. Jefferies, BofA Securities and Cantor are joint book‑running managers; LifeSci Capital and Oppenheimer are co‑lead managers; H.C. Wainwright and Ladenburg Thalmann are co‑managers. A preliminary prospectus supplement will be filed with the SEC.

Inhibikase Therapeutics (Nasdaq: IKT) plans to initiate a global pivotal Phase 3 study of IKT-001 in pulmonary arterial hypertension in Q1 2026. The adaptive two-part IMPROVE-PAH trial expects Part A as a double-blind, placebo-controlled study in 140 patients with primary endpoint PVR at Week 24, and Part B in 346 patients with primary endpoint 6MWD at Week 24. The design includes a 12-week dose-titration, uninterrupted enrollment between parts, and potential sample-size re-estimation; the study may run in about 180 global sites. IKT-001 is described as a prodrug of imatinib with expected improved gastrointestinal tolerability and a stated potential to accelerate an NDA timeline by ~3 years.

Inhibikase Therapeutics (Nasdaq: IKT) reported third quarter 2025 results and clinical progress on Nov 14, 2025. The company said it expects to initiate the Phase 2b IMPROVE-PAH trial of IKT-001 in Q4 2025, a randomized, double-blind, placebo-controlled study of ~150 PAH participants randomized 1:1:1 to 300 mg, 500 mg or placebo once daily for 26 weeks; primary endpoint is change in pulmonary vascular resistance at Week 26 and an interim safety review is planned at 12 weeks for ≥50 patients. Bioequivalence testing showed 500 mg IKT-001 has comparable exposure to 383 mg imatinib. Financials: cash and marketable securities were $77.3M as of Sept 30, 2025; Q3 net loss was $11.9M ($0.13/share). The company completed the CorHepta acquisition in Feb 2025 and named Timothy Pigot Chief Commercial and Strategy Officer.

Inhibikase Therapeutics (Nasdaq: IKT) has appointed Timothy Pigot as Chief Commercial and Strategy Officer to strengthen its leadership team. Pigot brings over 30 years of pharmaceutical industry experience, most recently serving as Chief Commercial Officer at Aerovate Therapeutics.

The appointment comes as Inhibikase advances IKT-001 toward late-stage clinical trials in pulmonary arterial hypertension (PAH). Pigot's extensive background includes leadership roles at MyoKardia, Gilead Sciences, and Pfizer, where he led commercial strategies for various therapeutic areas including PAH, cardiopulmonary, CNS, and oncology.

Inhibikase Therapeutics (Nasdaq: IKT) reported Q2 2025 financial results and provided updates on its PAH drug development program. The company is preparing to launch IMPROVE-PAH, a Phase 2b clinical study for IKT-001, their re-engineered prodrug of imatinib mesylate, in the second half of 2025.

The study will involve 150 PAH participants randomized to receive either 300mg IKT-001, 500mg IKT-001, or placebo. Previous studies showed imatinib's efficacy in PAH, with patients on 400mg achieving a 45-meter improvement in 6-minute walk distance. The company ended Q2 2025 with $87.7 million in cash and reported a net loss of $9.9 million ($0.11 per share).

Inhibikase Therapeutics (NASDAQ: IKT) reported its Q1 2025 financial results and recent developments. The company reported a net loss of $13.7 million ($0.15 per share) compared to $4.6 million in Q1 2024. R&D expenses increased to $10.5 million, including a $7.4 million non-cash charge for the CorHepta acquisition. SG&A expenses rose to $5.2 million from $2.0 million year-over-year.

The company strengthened its leadership team with key appointments, including Mark Iwicki as CEO. IKT is advancing IKT-001 toward a Phase 2b clinical trial in Pulmonary Arterial Hypertension (PAH) expected to begin in H2 2025. The company maintains a strong cash position of $93.2 million as of March 31, 2025.

Inhibikase Therapeutics (Nasdaq: IKT) has appointed David McIntyre as Chief Financial Officer, effective April 14, 2025. McIntyre brings over two decades of executive experience in the life sciences sector, having served in C-suite positions at companies including Anthos Therapeutics, HeartWare International, AVITA Medical, Tessa Therapeutics, and Braeburn.

Prior to joining IKT, McIntyre was a Partner at Apple Tree Partners, a multi-billion-dollar life sciences venture capital fund. His background includes roles as a senior attorney at Baker McKenzie and KPMG, focusing on M&A, IPOs, and corporate law. He holds degrees from the University of Sydney, University of Technology Sydney, and an MBA from Duke University's Fuqua School of Business.

Inhibikase Therapeutics (IKT) reported its 2024 financial results and key developments, highlighting a strategic focus on advancing IkT-001 for Pulmonary Arterial Hypertension (PAH) treatment. The company secured $110 million through a private placement in October 2024, with potential additional proceeds of up to $275 million if warrants are exercised.

Key financial metrics for 2024 include:

• Net loss of $27.5 million ($1.16 per share) vs $19.1 million in 2023
• R&D expenses increased to $17.2 million from $13.6 million in 2023
• SG&A expenses rose to $11.4 million from $6.7 million in 2023
• Cash position of $97.5 million as of December 31, 2024

The company strengthened its leadership team with Mark Iwicki as CEO, Chris Cabell as President and Head of R&D, and John Adams as CSO. The FDA issued a Study May Proceed letter for IkT-001's Phase 2b trial in September 2024.

Inhibikase Therapeutics (Nasdaq: IKT) has announced significant leadership appointments, strengthening its executive team with expertise in pulmonary arterial hypertension (PAH). Chris Cabell, MD, former Chief Medical Officer of Arena Pharmaceuticals and CEO of CorHepta, joins as President and Head of Research & Development. John Adams, PhD, CorHepta co-founder and former Head of Research at Arena Pharmaceuticals, becomes Chief Scientific Officer.

The company also appointed Vince Aurentz to its Board of Directors, bringing extensive experience in corporate strategy and business development from his role as Executive VP and Chief Business Officer at Arena Pharmaceuticals, which was acquired by Pfizer for $6.7 billion in 2022.

These appointments aim to accelerate the preparation and execution of the IkT-001 Phase 2 clinical trial in PAH. Both Cabell and Adams have significant experience with PAH medicine development, notably with ralinepag, which was successfully licensed to United Therapeutics.